Tresiba (insulin degludec) and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026. Fiasp's price will be reduced by 75%, making it the same price as NovoLog (insuin aspart), while ...
In 2015, the FDA finally approved Tresiba (insulin degludec) and Ryzodeg (insulin aspart and insulin degludec) on the basis of an interim analysis from DEVOTE. The primary endpoint of the DEVOTE ...
The approval covers all 27 European Union member states. Tresiba (insulin degludec) is a once-daily new-generation based insulin analogue with an ultra-long duration of action. Ryzodeg (insulin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback